All Releases
 |
NIAID Grant to Fund Dynavax Research on Hepatitis B Vaccination and Individual Variations in Human Responsiveness
Aug 31, 2010
|
7.3 KB |
|
| |
BERKELEY, CA, Aug 31, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today a grant from the National Institute of Allergy and Infectious Diseases (NIAID) to take a systems biology approach to study the differences between individuals that do or do not respond to vaccination against the Hepatit...
|
|
Dynavax Reports 2010 Second Quarter Financial Results
Jul 30, 2010
|
15.0 KB |
|
| |
BERKELEY, CA, Jul 30, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the second quarter ended June 30, 2010, including $57.4 million in cash and cash equivalents. This compared to $30.1 million at March 31, 2010. In April, the Company completed a financing which resu...
|
|
Dynavax to Present at the Wedbush Life Sciences Conference
Jul 29, 2010
|
7.2 KB |
|
| |
BERKELEY, CA, Jul 29, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it plans to present at the Wedbush Life Sciences Best Ideas Conference 2010 on Tuesday, August 3, 2010 at 8:00 am Eastern Time (5:00 am Pacific Time) at the Le Parker Meridien Hotel in New York.
Dynavax plans t...
|
|
Dynavax Promotes J. Tyler Martin, M.D. to President
Jul 27, 2010
|
7.5 KB |
|
| |
BERKELEY, CA, Jul 27, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the promotion of J. Tyler Martin, M.D. to the newly-created position of President and the appointment of Dr. Martin to the company's Board of Directors. Dr. Martin joined Dynavax as Chief Medical Officer in February 200...
|
|
Dynavax Completes Enrollment and First Immunizations in Universal Flu Vaccine Study
Jul 27, 2010
|
9.2 KB |
|
| |
BERKELEY, CA, Jul 27, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported completing enrollment and the first immunizations of 39 subjects enrolled in its Phase 1 study of the company's Universal Flu vaccine. Safety and immunogenicity data from this study are anticipated in the fourth quarter ...
|
|
Dynavax Reports New Employment Inducement Awards
Jul 23, 2010
|
7.0 KB |
|
| |
BERKELEY, CA, Jul 23, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) reported that equity awards were made to two new employees under the Company's 2010 Employment Inducement Award Plan ("the 2010 Plan"). The employees were granted options to purchase an aggregate of 13,000 shares of the Company's commo...
|
|
Dynavax Appoints Daniel Kisner, M.D. to Board of Directors
Jul 22, 2010
|
7.5 KB |
|
| |
BERKELEY, CA, Jul 22, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the appointment of Daniel Kisner, M.D. to its Board of Directors. The addition of Dr. Kisner to the Dynavax Board brings its membership to 10.
Dr. Kisner most recently served as a Partner at Aberdare Ventures and pr...
|
|
Dynavax Initiates First Human Trial in Universal Flu Vaccine Program
Jul 7, 2010
|
10.1 KB |
|
| |
BERKELEY, CA, Jul 07, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the first human clinical trial in its Universal Flu vaccine program. The Phase 1 trial, which began vaccinating subjects in late June, will assess the safety and immunogenicity of N8295, the novel component of Dynavax's...
|
|
Dynavax Awarded NIH Grant to Explore Feasibility of Universal Papilloma Virus Vaccine
Jul 6, 2010
|
7.0 KB |
|
| |
BERKELEY, CA, Jul 06, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the award of a $600,000 grant from the National Institutes of Health (NIH) to explore the feasibility of developing a universal vaccine to prevent infection by human papilloma virus (HPV). In contrast to the two approve...
|
|
NATURE Publishes New Dynavax Findings on Novel Role of TLRs in Lupus
Jun 16, 2010
|
9.9 KB |
|
| |
BERKELEY, CA, Jun 16, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported in NATURE new data that may explain the resistance of lupus patients to glucocorticoid treatment. In the June 16, 2010 issue of NATURE, Dynavax scientists show that activation of cells of the innate immune system by two ...
|
|
Dynavax's Two Phase 3 HEPLISAV Trials Cleared by DSMB to Continue Immunizations
May 27, 2010
|
9.3 KB |
|
| |
BERKELEY, CA, May 27, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Data Safety Monitoring Board (DSMB) established for Dynavax's two ongoing Phase 3 trials for HEPLISAV(TM) has completed the second of its planned safety assessments. The evaluation included data from 2,264 subj...
|
|
Dynavax Completes Over 2000 First Immunizations in Phase 3 Study
May 6, 2010
|
9.5 KB |
|
| |
BERKELEY, CA, May 06, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported completing the first immunizations of over 2,000 subjects enrolled in its large-scale Phase 3 study of HEPLISAV(TM). This starts a 12-month follow-up on these subjects and sets the study's completion for May 2011. Dynava...
|
|
Dynavax Reports 2010 First Quarter Financial Results
May 6, 2010
|
14.3 KB |
|
| |
BERKELEY, CA, May 06, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today reported financial results for the first quarter ended March 31, 2010, including $30.1 million in cash and cash equivalents. Total cash for the first quarter 2010 does not include $41 million in net proceeds from the public offer...
|
|
Dynavax's Two Phase 3 HEPLISAV Trials Cleared by DSMB to Continue Immunizations
Apr 27, 2010
|
9.3 KB |
|
| |
BERKELEY, CA, Apr 27, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced that the Data Safety Monitoring Board (DSMB) established for Dynavax's two ongoing Phase 3 trials for HEPLISAV(TM) has assessed subject safety data for 1,548 subjects that received their first injection and 1,225 subjec...
|
|
Dynavax Reports Positive Data on Universal Flu Vaccine Candidate
Apr 26, 2010
|
10.3 KB |
|
| |
BERKELEY, CA, Apr 26, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today presented preclinical data that confirms the expected immunogenicity and mechanistic effects of its Universal Flu vaccine. In addition to the demonstrated ability of Dynavax's vaccine to generate cytotoxic T-cells and cytotoxic a...
|
|
Dynavax's Chronic Kidney Disease Study Confirms HEPLISAV's Enhanced Seroprotection Against HBV Infection
Apr 14, 2010
|
11.1 KB |
|
| |
BERKELEY, CA, Apr 14, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today presented Phase 2 clinical data that demonstrate HEPLISAV(TM)'s immunogenicity and rapid protection in patients with chronic kidney disease. In a poster session at the National Kidney Foundation Spring Clinical Meeting in Orlando...
|
|
Dynavax Raises $44 Million Through Public Offering of Common Stock and Warrants
Apr 13, 2010
|
10.4 KB |
|
| |
BERKELEY, CA, Apr 13, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today announced the pricing of an underwritten offering resulting in gross proceeds of $44 million, before deducting estimated offering expenses. 30,293,000 units are being sold at a per unit price of $1.4525. Each unit consists of one...
|
|
Dynavax Announces New Employment Inducement Awards
Apr 9, 2010
|
7.2 KB |
|
| |
BERKELEY, CA, Apr 09, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) reported that equity awards were made to two new employees under the Company's 2010 Employment Inducement Award Plan ("the 2010 Plan"). The employees are focused on clinical and commercial development. Dynavax's Board of Directors adop...
|
|
Dynavax Reports Positive Findings From Detailed Safety Analysis of HEPLISAV(TM)
Mar 23, 2010
|
12.6 KB |
|
| |
BERKELEY, CA, Mar 23, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) will present for the first time a detailed analysis of safety data for HEPLISAV(TM), an investigational adult hepatitis B vaccine, including two major findings:
-- The safety profile of HEPLISAV was comparable to that of
En...
|
|
Dynavax Anticipates Earlier BLA Submission for HEPLISAV(TM)
Mar 16, 2010
|
18.3 KB |
|
| |
BERKELEY, CA, Mar 16, 2010 (MARKETWIRE via COMTEX News Network) -- Dynavax Technologies Corporation (NASDAQ: DVAX) today said that its large-scale Phase 3 study of HEPLISAV(TM) is fully enrolled, with immunization of subjects proceeding in accordance with the pre-specified safety monitoring plan. Dynavax indicated that it expects immunization of al...
|
|
|
